Rare dermatology focus Target opportunities in rare dermatologic diseases where there is unmet medical need, aligning outreach with Patagonia Pharmaceuticals’ niche focus and Phase 2a PAT-001 program.

Clinical stage leverage Position partnerships and oncology/dermatology collaborations around their clinical-stage status to attract biotech or specialty pharma seeking early-stage assets and potential licensing deals.

Strategic licensing Highlight past global licensing with Almirall as a proof point for successful collaborations, and pursue new license or co-development discussions to scale PAT-001.

Recent activity cues Capitalize on Phase 2a completion news to initiate conversations with potential sponsors, distributors, or CROs for pivotal studies, manufacturing partnerships, or regional rights discussions.

Resource-constrained buyer targets Given revenue under one million and a lean team, pursue strategic partnerships with mid-sized pharma, contract manufacturers, or specialty distributors that can add scale without large internal overhead.